Irodalom:
1. Kappelmann MD, Rifas-Shiman SL, Kleinman K, et al: The prevalenve and geographic distribution of
Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol 2007;5:1424-1429.
2. Jess T, Gamborg M, Munkholm P, et al: Overall and cause-specific mortality in ulcerative colitis: metaanalysis
of population-based inception cohort studies. Am J Gastroenterol 2007;102:609-617.
3. Dorn SD, Sandler RS.: Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality:
results from a systematic review and meta-analysis. Am J Gastroenterol 2007,102:662-667.
4. Aldous MC, Drummond HE, Anderson N, Satsangi J, et al: Does cigarette smoking influence the
phenotype of Crohn’s disease? Analysis using the Montreal classification. Am J Gastroenterol
2007;102:577-588.
5. Aldous MC, Drummond HE, Anderson N, Satsangi J, et al: Smoking habit and load influence age at
diagnosis and disease extent in ulcerative colitis. Am J Gastroenterol 2007;102:589-597.
6. Kaplan GG, Pedersen BV, Andersson RE, Korzenik S, et al: The risk of Crohn’s disease after an
appendectomy: a population-based cohort study in Sweden and Denmard. Gut 2007;56:1387-1392.
7. Rodemann JF, Dubberke ER, Reske KA, et al: Incidence of Clostridium difficile infection in inflammatory
bowel disease. Clin Gastroenterol Hepatol 2007;5:339-344.
8. Issa M, Vijayapal A, Graham MB, et al: Impact of Clostridium difficile on inflammatory bowel disease.
Clin Gastroenterol 2007;5:345-351.
9. Amre DK, D’Souza S, Morgan K, et al: Imbalances in dietary consumption of fatty acids, vegetables,
and fruits are associated with risk for Crohn’s disease in children. Am J Gastroenterol 2007;102:2016-2025.
10. Solberg IC, Vatn MH, Høie O, et al: and the IBSEN STUDY GROUP. Clinical course in Crohn’s disease:
results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007;
5:1430-1438.
11. Henriksen M, Jahnsen J, Lygren I.: Moum B, and the IBSEN Study Group. Are there any differences
in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease?
Results of a population-based follow-up study. Am J Gastroenterol 2007;102:1955-1965.
12. Karban A, Itay M, Davidovich O, et al: Risk factors for perianal Crohn’s disease: the role of genotype,
phenotype, and ethnicity. Am J Gastroenterol 2007;102:1702-1708.
13. Guitart J.: Management of dermatologic complications of inflammatory bowel disease. Am J Gastroenterol
2007;102:S68-S71.
14. Mahadevan U, Sandboern WJ, Li D-K, et al: Pregnancy outcomes in women with inflammatory bowel
disease: a large, community-based study from Northern California. Gastroenterology 2007;133:1106-1112.
15. Heetun ZS, Byrnes C, Neary P, O’Morain CO. Review article: reproduction in the patient with inflammatory
bowel disease. Aliment Pharmacol Ther 2007;26:513-533.
A vastagbél 241
16. D’Haens G, Sandborn WJ, Feagan BG, et al: A review of activity indices and efficacy end points for
clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-786.
17. Langhorst J, Elsenbruch S, Koelzer J, et al: Noninvasive markers in the assessment of intestinal
inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and
PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103:162-169.
18. Mamula P, Markowitz JE, Piccoli DA, et al: Immune response to influenza vaccine in pediatric patients
with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:851-856.
19. Gupta RB, Harpaz N, Itzkowitz S, et al: Histologic inflammation is a risk factor for progression to
colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007;133:1099-1105.
20. Vleggar FP, Lutgens MWMD, Claessen MMH. Review article: the relevance of surveillance endoscopy
in long-lasting inflammatory bowel disease. Aliment Pharmacol Ther 2007;26(Suppl 2):47-52.
21. Su C, Lewis JD, B. Goldberg, G. Lichtenstein: A meta-analysis of the placebo rates of remission and
response in clinical trials of active ulcerative colitis. Gastroenterology 2007;132:516-526.
22. Safdi AV, Cohen RD. Review article: increasing the dose of oral mesalazine therapy for active ulcerative
colitis does not improve remission rates. Aliment Pharmacol Ther 2007;26:1179-1186.
23. D’Haens G, Hommes D, Engels L, et al: Once daily MMX mesalazine for the treatment of mildto-moderate
ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther 2006;24:1087-1097.
24. Kamm MA, Sandborn WJ, Gassull M, et al: Once-daily, high-concentration MMX mesalamine in active
ulcerative colitis. Gastroenterology 2007;132:66-75.
25. Sandborn WJ, Kamm MA, Lichtenstein GR, et al: MMX Multi Matrix System mesalazine for the
induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two
randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007;26:205-215.
26. Steinhart A, Forbes A, Mills EC, Travis SPL, et al: Systematic review: the potential influence of
mesalazine formulation on maintenance of remission in Crohn’s disease. Aliment Pharmacol Ther
2007;25:1389-1399.
27. Torner D, Walsh CM, Steinhart AH, Griffiths AM.: Response to corticosteroids in severe ulcerative colitis:
a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007;5:103-110.
28. Gustavsson A, Halfvarson J, Magnuson A et al: Jarnerot G. Long-term colectomy rate after intensive
intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era.
Am J Gastroenterol 2007;2513-2519.
29. Manguso F. Balzano A.: Meta-analysis: the efficacy of rectal beclomathasone dipropionate vs.
5aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment Pharmacol Ther 2007;26:21-29.
30. Turner D, Grossman AB, Rosh J, et al: Methotrexate following unsuccessful thiopurine therapy in
pediatric Crohn’s disease. Am J Gastroenterol 2007;102:2804-2812.
31. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB.: Effect of allopurinol on clinical outcomes
in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol
Hepatol 2007;5:209-214.
32. Shaye OA, Yadegari M, Abreu MT, et al: Hepatotoxicity of 6-mercaptopurine (6-MP) and azathioprine
(AZA) in adult IBD patients. Am J Gastroenterol 2007;102:2488-2494.
33. Nørgård B, Pedersen L, Christensen LA, Sørensen HT.: Therapeutic drug use in women with Crohn’s
disease and birth outcomes: a danish nationwide cohort study. Am J Gastroenterol 2007;102: 14056-1413.
34. Selby W, Pavli P, Crotty B, et al: Two-year combination antibiotic therapy with clarithromycin, rifabutin,
and Clofazimine for Crohn’s disease. Gastroenterology 2007;132:2313-2319.
242 Gastro Update 2008
35. Shen J, Ran ZH, Tong JL, Xiao SD.: Meta-analysis: the utility and safety of heparin of heparin in the
treatment of active ulcerative colitis. Aliment Pharmacol Ther 2007;26:653-663.
36. Schreiber S, Keshavarzian A, Isaacs KL, Hanauer SB, et al: A randomized, placebo-controlled, phase
II study of tetomilast in active ulcerative colitis. Gastroenterology 2007;132:96-88.
37. Abitol V, Briot K, Roux C, et al: A double-blind placebo-controlled study of intravenous clodronate for
prevention of steroid-induced bone loss in inflammatory bowel disease. Clin Gastroenterol Hepatol
2007;5:1184-1189.
38. Johnson FR, Özdemir S, Mansfield C, Sands B, et al: Crohn’s disease patients’ risk-benefit preferences:
serious adverse event risk versus treatment efficacy. Gastroenterology 2007;133:769-779.
39. East JE, Brooker JC, Rutter MD, Saunders BP.: A pilot study of intrastricture steroid versus placebo
injection after balloon dilatation of Crohn’s strictures. Clin Gastroenterol Hepatol 2007;5:1065-1069.
40. Bokemayer B, Teml A, Roggel C, et al: Adherence to thiopurine treatment in out-patients with Crohn’s
disease. Aliment Pharmacol Ther 2007;26:217-225.
41. Fedorak RN.: Probiotics in the management of inflammatory bowel disease? Am J Gastroenterology
2007;102:S22-S28.
42. Jonkers D, Stockbrügger R.: Review article: probiotics in gastrointestinal and liver diseases. Aliment
Pharmacol Ther 2007;26(Suppl 2):133-148.
43. Barclay ML, Ailabouni L, Gearry RB, et al: Complementary and alternative medicine use in IBD is
determined by age, sex and socioeconomic status and is no different in controls without IBD. Gut;56
(Suppl III):A151.
44. Hoie O, Wolter FL, Riis L, and al: on behalf of the European Collaborative Study Group of Inflammatory
Bowel Disease. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for
10 years. Gastroenterology 2007;132:132:507-515.
45. Aratari A, Papi C, Leandro G, et al: Caprilli R. Early versus late surgery for ileo-coecal Crohn’s disease.
Aliment Pharmacol Ther 2007;26:1303-1312.
46. Shen B.: Managing pouchitis. Am J Gastroenterol 2007;102:S60-S64.
47. Fleshner P, Ippoliti A, Dubinsky M, et al: Targan S. A prospective, multivariate analysis of clinical factors
associated with pouchitis after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2007;5:952-958.
48. Taminiau JA.: Review article: the clinical importance of growth in children with inflammatory bowel
disease: is it important to the gastroenterologist? Aliment Pharmacol Ther 2007;26(Suppl 2):53-56.
49. Bernard A, Langille M, Hughes S, et al: A systematic review of patient inflammatory bowel disease
information resources on the world wide Web. Am J Gastroenterol 2007;102:2070-2077.
50. Johnson IT, Lund EK.: Review article: nutrition, obesity and colorectal cancer. Aliment Pharmacol Ther
2007;26:161-181.
51. Yang Y-X, Henessy S, Propert K, et al: Chronic proton pump inhibitor therapy and the risk of colorectal
cancer. Gastroenterology 2007;133:748-754.
52. Robertson DJ, Larsson H, Friis S, et al: Proton pump inhibitor use and risk of colorectal cancer: a
population-based, case-control study. Gastroenterology 2007;133:755-760.
53. Mecklin J-P, Aarnio M, Laara E, et al: Development of colorectal tumor in colonoscopic surveillance
in Lynch Syndrome. Gastroenterology 2007;133:1093-1098.
54. Brosens LAA, van Hattem A, Hilind LM, et al: Risk of colorectal cancer in juvenile polyposis. Gut
2007;56:965-967.
A vastagbél 243
55. Durno C, Monga N, Bapat B, et al: Does early colectomy increase desmoid risk in familial adenomatous
polyposis? Clin Gastroenterol Hepatol 2007;5:1190-1194.
56. Brenner H, Hoffmeister M, Stegmaier C, et al: Risk of progression of advanced adenomas to colorectal
cancer by age and sex: estimates based on 840 149 screening colonoscopies. Gut 2007;56:1585-1589.
57. Chan AT, Ogino S, Fuchs CS.: Aspirin and the risk of colorectal cancer in relation to the expression of
COX-2. N Engl J Med 2007;356:2131-2142.
58. Lanas A, Baron JA, Sandler RS, et al: Peptic ulcer and bleeding events associated with rofecoxib in a
3-year colorectal adenoma chemoprevention trial. Gastroenterology 2007;132:490-497.
59. Kerr DJ, Dunn JA, Langman MJ, et al: for the Victor Triap Group. Rofecoxib and cardiovascular
adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007;357:360-369.
60. Poynter JN, Gruber SB, Higgins PDR, et al: Statins and the risk of colorectal cancer. N Engl J Med
2005;352:2184-2192.
61. Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF.: Risk of colorectal cancer in patients prescribed
statins, nonsteroidal anti-inflammatory drugs, and Cyclooxygenase-2 inhibitors: nested case-control
study. Gastroenterology 2007;133:393-402.
62. Sponzi G, Dal Fante M, Masci E, and SIED Lombardia Working Group, Italy: Lack of colonic neoplastic
lesions in patients under 50 yr of age with hematochezia: a multicenter prospective study. Am J
Gastroenterol 2007;102:2011-2015.
63. Guittet L, Bouvier V, Mariotte N, et al: Comparison of a guaiac based and an immunochemical faecal occult
blood test in screening for colorectal cancer in a general average risk population. Gut 2007;56:210-214.
64. Jung H-K, Halder S, McNally M, Talley N, et al: Overlap of gastro-oesophageal reflkux disease and
irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol
Ther 2007;26:453-461.
65. Nyrop KA, Palsson OS, Levy RL, Whitehead WE, et al: Costs of health care for irritable bowel syndrome,
chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther
2007;26:237-248.
66. Kassinen A, Krogius-Kurikka L, Mûkivoukko H, et al: The fecal microbiota of irritable bowel syndrome
patients differs significantly from that of healthy subjects. Gastroenterology 2007;133;24-33.
67. Thabane M, Kottochchi DT, Marshall JK.: Systematic review and meta-analysis: the incinence and
prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007;26:535-544.
68. Törnblom H, Svenungsson B, Lindberg G.: Gastrointestinal symptoms after infectious diarrhea: a five-year
follow-up in a swedish cohort of adults. Clin Gastroenterol Hepatol 2007;5:461-464.
69. Frissora CL. Cash BD.: Review article: the role of antibiotics vs. conventional pharmacotherapy in
treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 2007;25:1271-1281.
70. Posserud I, Syrous A, Lindström L, et al: Altered rectal perception in irritable bowel syndrome is
associated with symptom severity. Gastroenterology 2007;133:1113-1123.
71. Halder SLS, Locke III. GR, Schleck CD, Talley N, et al: Natural hystory of functional gastrointestinal
disorders: a 12-year longitudinal population-based study. Gastroenterology 2007;133:799-807.
72. Garrigues V, Mearin F, Badia X, et al: Change over time of bowel habit in irritable bowel syndrome: a
prospective, observational, 1-year, follow-up study (RITMO study). Aliment Pharmacol Ther 2007;25;323-332.
73. Kajander K, Myllyluoma E, Rajilic-Stojanovic M, et al: Clinical trial: multispecies probiotic supplementation
alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol
Ther 2008;27:48-57.
244 Gastro Update 2008
74. Lacy BE, Weiser K, Noddin L, et al: Irritable bowel syndrome: patients attitudes, concerns and level of
knowledge. Aliment Pharmacol Ther 2007;25:1329-1341.
75. Spiegel B, Schoenfelds P, Naliboff B.: Systemic review: the prevalence of suicidal behaviour in patients
with chronic abdominal pain and irritable bowel syndrome. Aliment Pharmacol Ther 2007;26:183-193.
76. Shen EP, Surawicz CM.: The changing face of Clostridium difficile: what treatment options remain?
Am J Gastroenterol 2007;102:2789-2792.
77. Rodriguez LAG, Ruigómez A.: Panés J. Use of acid-suppressing drugs and the risk of bacterial
gastroenteritis. Clin Gastroenterol Hepatol 2007;5:1418-1423.
78. Choung RS, Locke III GR, Schleck CD, et al: Cumulative incidence of chronic obstipation: a populationbased
study 1988-2003.
79. Freied M, Johanson JF, Gwee KA, et al: Efficacy of tegaserod in chronic constipation in men. Am J
Gastroenterol 2007;102:362-370.
80. Grinkemeier GMS, Cassara JE, Dalton CB, Drossman DA.: The narcotic bowel syndrome: clinical features,
pathophysiology, and treatment. Clin Gastroenterol Hepatol 2007;5:1125-1139.
